PA
PALI.O
—
NASDAQ
Biotechnology & Medical Research
Palisade Bio Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
-13,0 %
Net margin
—
Debt / equity
0,00
Beta
—
52w range
—
Volume
13,7k
Day range
$2,05–$2,15
Prev close
$2,07
Open
$2,05
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Palisade Bio Inc is a biotechnology company focused on healthcare diagnostics, developing and commercializing products for the detection and monitoring of infectious diseases and other health conditions.
Business. Palisade Bio Inc (PALI.O) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
BUY8 analysts
8 buy0 hold0 sell
Avg 12m price target10,00
Analyst recommendations
8 analysts · consensus BuyBuy8
Hold0
Sell0
12-month price target
10,00
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
8 analysts · indicative
Ownership→
JANUS HENDERSON GROUP PLC
largest disclosed fund holder
Profitability→
-13,0 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to PALI.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Palisade Bio Inc (PALI.O) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
AI synthesis
GENERATEDPalisade Bio Inc has a highly liquid capital structure, with cash and equivalents amounting to $133.39 million, significantly exceeding its total liabilities of $4.96 million, resulting in a current ratio of 28.95. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure with no leverage.
The company is currently unprofitable, with a net loss of $16.78 million and an operating loss of $18.06 million. Its return on equity is -12.97%, and its return on assets is -12.49%, both significantly below the industry median for biotechnology firms. These metrics suggest that the company is not generating returns on its equity or assets and is likely in a research and development phase.
Palisade Bio Inc does not disclose segment or geographic revenue breakdowns in its latest financial filings, making it difficult to assess revenue concentration or geographic exposure. However, the absence of such disclosures is common for early-stage biotechnology firms that may not yet have diversified operations or revenue streams.
The company is in a growth phase, as evidenced by its negative operating and free cash flows, which are typical for firms investing heavily in R&D. Analysts have provided a mean price target of $10.00 and a median price target of $7.50, with a mean recommendation of 1.75 (leaning toward buy). The company has no immediate filing-based liquidity or dilution flags, and its dilution risk is assessed as low.
The risk assessment for Palisade Bio Inc indicates low liquidity risk, supported by its strong cash position and absence of long-term debt. Dilution risk is also low, with no immediate filing-based flags detected. However, the company's unprofitability and negative cash flows pose operational risks, particularly if R&D efforts fail to yield commercializable products or if market conditions shift.
There are no recent filings or transcripts that indicate significant events or changes in the company's operations or strategy. The company appears to be in a stable but unprofitable phase, with a focus on R&D and product development. Analysts remain cautiously optimistic, with a strong-buy count of 2 and a buy count of 6, but no hold or sell recommendations.
Key takeaways
- Palisade Bio Inc has a highly liquid balance sheet with $133.39 million in cash and no long-term debt.
- The company is unprofitable, with a net loss of $16.78 million and negative returns on equity and assets.
- Analysts are cautiously optimistic, with a mean price target of $10.00 and a median of $7.50.
- The company has low liquidity and dilution risk, but its unprofitability and negative cash flows pose operational risks.
- No recent filings or transcripts indicate significant changes in the company's operations or strategy.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$2,01
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$129.4M
Net cashⓘ
$133.3M
Current ratioⓘ
28.9
Debt / equityⓘ
0.0
ROAⓘ
-12.5%
ROEⓘ
-13.0%
Cash conversionⓘ
65.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-0,20
Predicted surprise
+0,00
Beat probability
45 %
Analysts
8
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-22 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,20 |
| Revenue | —no estimate | —no estimate | 0 USD |
| Operating income | —no estimate | —no estimate | -40,1M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution8 analysts
Strong buy2
Buy6
Hold0
Sell0
Strong sell0
12-month price target$10,00 · Median $7,50
Low $5,00High $25,00
Operating income · consensus-40,1M USD
EPS surprise
−47,9 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$5,00
Mean$10,00
Median$7,50
High$25,00
Spot$2,01
+397.5 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
ROE-13,0 %Above median
D/E0,00Above median
Cash Conv0,65Below median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 22 795 301 sh5 exercises · 12 grants5 insiders
- Director · Restricted Stock Units → Common StockDisposed 20 200exercise · 2026-06-10
- Director · Restricted Stock Units → Common StockDisposed 20 200exercise · 2026-06-10
- Director · Restricted Stock Units → Common StockDisposed 60 666exercise · 2026-06-10
- Director, CEO, CFO · Restricted Stock Units → Common StockDisposed 13 333exercise · 2026-02-11
- Chief Medical Officer · Restricted Stock Units → Common StockDisposed 8 000exercise · 2026-02-11
- Chief Medical Officer · Restricted Stock Units → Common StockAcquired 787 000grant · 2026-02-09
- Director, CEO, CFO · Restricted Stock Units → Common StockAcquired 2 011 000grant · 2026-02-09
- Director, CEO, CFO · Restricted Stock Units → Common StockAcquired 9 179 400grant · 2025-10-06
- Director · Restricted Stock Units → Common StockAcquired 510 700grant · 2025-10-06
- Chief Medical Officer · Restricted Stock Units → Common StockAcquired 7 665 800grant · 2025-10-06
- Director · Restricted Stock Units → Common StockAcquired 510 700grant · 2025-10-06
- Director · Restricted Stock Units → Common StockAcquired 1 538 700grant · 2025-10-06
- Chief Medical Officer · Phantom Units → Common StockAcquired 289 000grant · 2025-09-04
- Director · Phantom Units → Common StockAcquired 64 400grant · 2025-09-04
- Director, CEO, CFO · Phantom Units → Common StockAcquired 323 400grant · 2025-09-04
- Director · Phantom Units → Common StockAcquired 18 800grant · 2025-09-04
- Director · Phantom Units → Common StockAcquired 18 800grant · 2025-09-04
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
Source documents
- Palisade Bio Inc Market data — financials · 2026-05-28
- Palisade Bio Inc Market data — analyst estimates · 2026-05-28
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,01 %$19M
- Institutional Investor · as of 2026-03-310,00 %$15M
- Investment Managers · as of 2026-03-310,00 %$10M
- Investment Managers · as of 2026-03-310,00 %$9M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$8M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2025-12-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Insider activity
Net buying2 buys · 2 sellsnet $7K7 insiders · last 365d
- Director · Common StockOther 592 300 · 2026-06-10
- Director · Common StockOther 60 666 · 2026-06-10
- Director · Common StockOther 20 200 · 2026-06-10
- Director · Common StockOther 336 904 · 2026-06-10
- Director · Common StockOther 336 904 · 2026-06-10
- Director · Common StockOther 592 300 · 2026-06-10
- Director · Common StockOther 20 200 · 2026-06-10
- Director · Common StockOther 1 498 900 · 2026-06-10
- Chief Medical Officer · Common StockSold 1 989 @ $1,75$3K · 2026-02-12
- Director, CEO, CFO · Common StockSold 3 896 @ $1,75$7K · 2026-02-12
- Director, CEO, CFO · Common StockOther 13 333 · 2026-02-11
- Chief Medical Officer · Common StockOther 8 000 · 2026-02-11
- Director · Common StockBought 5 000 @ $1,67$8K · 2026-01-16
- Director · Common StockBought 5 000 @ $1,88$9K · 2026-01-09
Short positioning
37.0Mshares short+15.2% vs prior
9.98days to cover
56.0%short of daily vol
410.0Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
PALI.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Evidence & claims
From filings & derived data- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 1,258.2%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -21.5%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 46.5%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 11.0%Derived (calculated)
- Return on equity (FY 2025-12-31): -13.0%Derived (calculated)
- Return on assets (FY 2025-12-31): -12.5%Derived (calculated)
- Current ratio (FY 2025-12-31): 28.95xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.04xDerived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -16.2%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 97.1%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 97.1%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 1,626.9%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 1,134.8%Derived (calculated)
- Total liabilities (annual): USD 4.96MSEC XBRL filing
- Operating cash flow (annual): USD -10.85MSEC XBRL filing
- Total assets (annual): USD 134.34MSEC XBRL filing
- Current liabilities (annual): USD 4.64MSEC XBRL filing
- Operating income (annual): USD -18.06MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
- Shareholders' equity (annual): USD 129.38MSEC XBRL filing
- Cash & equivalents (annual): USD 133.38MSEC XBRL filing
- Total operating expenses (annual): USD 18.06MSEC XBRL filing
- Net income (annual): USD -16.78MSEC XBRL filing
- Current assets (annual): USD 134.22MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-10 00:00 UTCINSIDER11 insider transactions — 2026-06 3 derivative
2026-06-10INSIDERChuang Emil transacted 592.3k sh — Director
2026-06-10INSIDERWilliams Donald Allen transacted 60.7k sh — Director
2026-06-10INSIDERChuang Emil transacted 20.2k sh — Director
2026-06-10INSIDERZwick Jordan Michael transacted 336.9k sh — Director
2026-06-10INSIDERBaltera Robert Jr. transacted 336.9k sh — Director
2026-06-10INSIDERWei Binxian transacted 592.3k sh — Director
2026-06-10INSIDERWei Binxian transacted 20.2k sh — Director
2026-06-10INSIDERWilliams Donald Allen transacted 1.50M sh — Director
2026-06-10INSIDERWilliams Donald Allen disposed of 60.7k sh Restricted Stock Units — Director
2026-06-10INSIDERWei Binxian disposed of 20.2k sh Restricted Stock Units — Director
2026-06-10INSIDERChuang Emil disposed of 20.2k sh Restricted Stock Units — Director
2026-02-12 00:00 UTCINSIDER8 insider transactions — 2026-02 4 derivative
2026-02-12INSIDERJones Mitchell Lawrence sold 2.0k sh — Chief Medical Officer ~$3k
2026-02-12INSIDERFinley John David sold 3.9k sh — Director, CEO, CFO ~$7k
2026-02-11INSIDERFinley John David transacted 13.3k sh — Director, CEO, CFO
2026-02-11INSIDERJones Mitchell Lawrence transacted 8.0k sh — Chief Medical Officer
2026-02-11INSIDERFinley John David disposed of 13.3k sh Restricted Stock Units — Director, CEO, CFO
2026-02-11INSIDERJones Mitchell Lawrence disposed of 8.0k sh Restricted Stock Units — Chief Medical Officer
2026-02-09INSIDERFinley John David acquired 2.01M sh Restricted Stock Units — Director, CEO, CFO
2026-02-09INSIDERJones Mitchell Lawrence acquired 787.0k sh Restricted Stock Units — Chief Medical Officer
2026-01-16 00:00 UTCINSIDER2 insider transactions — 2026-01
2026-01-16INSIDERWilliams Donald Allen bought 5.0k sh — Director ~$8k
2026-01-09INSIDERWilliams Donald Allen bought 5.0k sh — Director ~$9k
2025-10-06 00:00 UTCINSIDER5 insider transactions — 2025-10 5 derivative
2025-10-06INSIDERWilliams Donald Allen acquired 1.54M sh Restricted Stock Units — Director
Showing the 40 most recent of 51 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage